Ad is loading...
VISVX
Price
$50.61
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VSIAX
Price
$90.70
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

VISVX vs VSIAX

Header iconVISVX vs VSIAX Comparison
Open Charts VISVX vs VSIAXBanner chart's image
Vanguard Small Cap Value Index I
Price$50.61
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index Admiral
Price$90.70
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
VISVX vs VSIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VISVX vs. VSIAX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VISVX is a Buy and VSIAX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX (57.6B) and VSIAX (57.6B) have equal amount of cash in the bank . VSIAX pays higher dividends than VISVX: VSIAX (2.01) vs VISVX (1.90). VISVX was incepted earlier than VSIAX: VISVX (27 years) vs VSIAX (13 years). VISVX (16.00) and VSIAX (16.00) have comparable annual turnover. VISVX (3000) and VSIAX (3000) have matching initial minimum investment requirements. VSIAX (30.11) and VISVX (30.04) have marching annual gain over last year. VSIAX (62.31) and VISVX (62.14) have equivalent 5 years return.
VISVXVSIAXVISVX / VSIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years13 years-
Gain YTD17.71217.784100%
Front LoadN/AN/A-
Min. Initial Investment30003000100%
Min. Initial Investment IRAN/AN/A-
Net Assets57.6B57.6B100%
Annual Yield % from dividends1.902.0194%
Returns for 1 year30.0430.11100%
Returns for 3 years16.9216.99100%
Returns for 5 years62.1462.31100%
Returns for 10 years109.83110.4699%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics